Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis.

Jiao FengWeiqi DaiYuqing MaoLiwei WuJingjing LiKan ChenQiang YuRui KongSainan LiJie ZhangJie JiJianye WuWenhui MoXuanfu XuChuan-Yong Guo

Published in: Journal of experimental & clinical cancer research : CR (2020)

Simvastatin can inhibit the HIF-1α/PPAR-γ/PKM2 axis, by suppressing PKM2-mediated glycolysis, resulting in decreased proliferation and increased apoptosis in HCC cells, and re-sensitizing HCC cells to Sora.

Keyphrases

induced apoptosis
cell cycle arrest
endoplasmic reticulum stress
signaling pathway
oxidative stress
cell death
pi k akt
insulin resistance
endothelial cells
type diabetes
skeletal muscle